2012

Adalimumab in paediatric CD

Infliximab in postoperative recurrence in CD

Mesalazine in UC once or twice daily

Profermin is efficacious in patients with active ulcerative colitis–a randomized controlled trial

Rifaximin-Extended Intestinal Release Induces Remission in Patients With Moderately Active Crohn’s Disease

Secukinumab in mode-severe CD

Infliximab switch to adalimumab in CD

Tacrolimus in steroid dependent UC

Infliximab stop in CD

Glutamine and whey protein improve intestinal permeability and morphology in patients with Crohn’s disease: a randomized controlled trial